Savara Inc Stock Price, News & Analysis

Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company focused on rare respiratory diseases, announced on September 2, 2021, the grant of inducement awards to two new employees. The awards consist of options to purchase 200,000 shares and restricted stock units (RSUs) covering 75,000 shares of common stock. The options have an exercise price of $1.59 per share and a 10-year term while vesting quarterly. RSUs vest in full after two years of employment. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan, per NASDAQ Listing Rules.

Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focusing on rare respiratory diseases, announced the grant of inducement awards to two new employees on August 16, 2021. These awards comprise options for 200,000 shares and restricted stock units (RSUs) for 100,000 shares, granted under the 2021 Inducement Equity Incentive Plan. The options have an exercise price of $1.19 per share and a 10-year term, with quarterly vesting. RSUs will vest fully after two years, contingent on continued employment.

Savara Inc. (NASDAQ: SVRA) reported its financial results for Q2 ending June 30, 2021. The company registered a net loss of $10.9 million or $(0.07) per share, an improvement from the $9.4 million loss or $(0.16) per share in the same quarter last year. Research and development expenses rose by 19.3% to $7.3 million, driven by the molgramostim development program. Savara's cash position stands at $181 million, with $25 million in debt. The pivotal Phase 3 IMPALA 2 trial is in progress, following successful patient dosing and site activation.

Savara Inc. (Nasdaq: SVRA) has announced the dosing of the first patient in the pivotal IMPALA-2 clinical trial, designed to evaluate the efficacy and safety of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP). This Phase 3 trial will enroll approximately 160 patients across ~50 sites globally. Despite the previous IMPALA trial not meeting its primary endpoint, supportive secondary data showed potential benefits of molgramostim. The FDA granted Breakthrough Therapy Designation for molgramostim in aPAP in December 2019, highlighting its significance in addressing unmet medical needs.

Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the Jefferies Virtual Healthcare Conference. The presentation is scheduled for June 2, 2021, at 10:00 AM ET. Interested parties can access the live audio webcast on Savara's Investors page, with an archived version available for 90 days post-event. The company’s primary focus is on its molgramostim nebulizer solution, currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara Inc. (Nasdaq: SVRA) announced its participation in the Oppenheimer Rare & Orphan Disease Virtual Summit scheduled for May 21, 2021, at 12:25 PM ET. The management will present information about the company's focus on rare respiratory diseases, particularly its lead program, molgramostim nebulizer solution, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Interested parties can access the live audio webcast on Savara's website.

Archived presentations will be available for 90 days following the event.

Savara Inc. (Nasdaq: SVRA) announced on May 11, 2021, the granting of stock options and restricted stock units (RSUs) to a new employee. This includes options to purchase 175,000 shares at an exercise price of $1.62, the closing price on the grant date. The options will vest quarterly over four years, while the RSUs will fully vest after two years. Savara specializes in developing treatments for rare respiratory diseases, focusing on its lead program, molgramostim, currently in Phase 3 for autoimmune pulmonary alveolar proteinosis.

Savara Inc. (Nasdaq: SVRA) reported a net loss of $10.2 million or $(0.13) per share for Q1 2021, an improvement from a loss of $15.4 million or $(0.27) per share in Q1 2020. The company reduced R&D expenses by 42.5% to $7.6 million, mainly due to the absence of costs related to the acquisition of Apulmiq. Savara raised $130 million in equity, enhancing its cash position to approximately $193 million, expected to fund operations through 2025. The IMPALA-2 trial's site activation is underway, with early patient randomization anticipated by late Q2 or early Q3 2021.

Savara Inc. (Nasdaq: SVRA) announced the completion of an underwritten public offering of 57,479,978 shares of common stock at $1.45 each, raising approximately $130 million before fees. This includes 11,694,150 shares purchased via underwriters' full exercise of their option. Additionally, pre-funded warrants for 32,175,172 shares were sold at $1.449 each. The funds will be allocated towards operational costs, particularly for the clinical development of molgramostim in autoimmune pulmonary alveolar proteinosis and broader working capital needs.